• Orchestra BioMed launched an underwritten public offering of common stock, with all shares offered by the company.
• Underwriters will receive a 30-day option to purchase additional shares equal to up to 15% of the offering.
• Net proceeds will support AVIM Therapy and Virtue SAB programs, including pivotal trials, alongside other development and general corporate purposes.
• Piper Sandler and TD Cowen are joint bookrunning managers; BTIG is a bookrunner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871715) on November 05, 2026, and is solely responsible for the information contained therein.